Author

Hélène Ribault

Observed names: H. Ribault, Helene Ribault

Institution: UniCancer Group

Observed institution: UniCancer Group

OpenAlex ID: A5036085547

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

2024 · Alberto Bossi, Stéphanie Foulon, et al. · The Lancet · 112

Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

2023 · Alberto Bossi, Stéphanie Foulon, et al. · Journal of Clinical Oncology · 59

Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.

2023 · Loic Mourey, Helen Jane Boyle, et al. · Journal of Clinical Oncology · 22

1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial

2022 · G. Gravis Mescam, X. Maldonado, et al. · Annals of Oncology · 17

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial

2025 · Guilhem Roubaud, Marie Kostine, et al. · European Journal of Cancer · 15

Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.

2022 · Guilhem Roubaud, Marie Kostine, et al. · Journal of Clinical Oncology · 5

1595MO Phenotypic and genomic characterization of de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase III trial

2024 · C. Pobel, C. Bargain, et al. · Annals of Oncology · 3

1421P Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial

2022 · A. Bernard-Tessier, M. Cancel, et al. · Annals of Oncology · 3

Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS.

2024 · Nataniel Hernan Lester-Coll, David Joseph Benjamin, et al. · Journal of Clinical Oncology · 2

Predictive value of a pathomics signature in de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase 3 trial.

2026 · Cedric Pobel, Imane Chraki, et al. · Journal of Clinical Oncology

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial

2025 · Adrien Rousseau, Maryam Karimi, et al. · European Journal of Cancer

2802O Home-based supervised physical activity (SPA) for metastatic cancer patients receiving oral targeted therapy: The AFSOS-Unicancer QUALIOR randomized phase III study

2025 · F. Joly Lobbedez, C. Lefeuvre-Plesse, et al. · Annals of Oncology

Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysis

2025 · Najlaa Alyamani, Enrico Clementel, et al. · Radiotherapy and Oncology

OC-0609 Radiotherapy quality assurance of the PEACE-1 trial: Initial results of individual case reviews

2022 · N. Alyamani, P. Sargos, et al. · Radiotherapy and Oncology

Works count: 14

Citation count: 238

H-index: 5

I10-index: 5